Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
暂无分享,去创建一个
A. Tsao | D. Gibbons | F. Fossella | Jianjun Zhang | X. Le | B. Carter | Y. Elamin | F. Mott | G. Blumenschein | M. Altan | V. Lam | M. Negrão | J. Robichaux | A. Patel | J. Heymach | Lei Feng
[1] C. Dooms,et al. Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5) , 2021, Clinical Trials.
[2] M. Socinski,et al. 36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer , 2021 .
[3] M. Socinski,et al. LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations , 2020 .
[4] Jianxing He,et al. Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Jänne,et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. , 2020 .
[6] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.
[7] Joe Y. Chang,et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[8] Jing Wang,et al. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. , 2019, Cancer cell.
[9] A. Drilon,et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] H. Ji,et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] P. Jänne,et al. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. , 2018, Lung cancer.
[12] Xiangdong Zhou,et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] S. Swisher,et al. Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. , 2018 .
[14] Kwok-Kin Wong,et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer , 2018, Nature Medicine.
[15] J. Hainsworth,et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Berger,et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] G. Doherty,et al. Activating HER2 mutations as emerging targets in multiple solid cancers , 2017, ESMO Open.
[18] A. Redig,et al. Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. , 2017, Cancer research.
[19] F. Cappuzzo,et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] G. Giaccone,et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Bei Yang,et al. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study , 2015, Journal of Molecular Modeling.
[22] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Peters,et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[25] I. Umelo,et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. , 2012, Lung cancer.
[26] Irene Manrique,et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model , 2010, BMC Cancer.
[27] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[28] Carlos L Arteaga,et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.
[29] W. Park,et al. Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.
[30] J. Minna,et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.
[31] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Dancey,et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] P F Thall,et al. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. , 1998, Statistics in medicine.
[34] P F Thall,et al. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.